Press Releases

Press Releases

    Date Title View
    04/16/21
    Summary ToggleNew Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
    PDF Version
    04/12/21
    Summary ToggleHorizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
    PDF Version
    04/08/21
    Summary ToggleHorizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
    PDF Version
    04/07/21
    Summary ToggleRECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil
    PDF Version
    04/05/21
    Summary ToggleNew UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology’s 73rd Annual Meeting
    PDF Version
    03/30/21
    Summary ToggleHorizon Therapeutics plc to Resupply Market With TEPEZZA® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April
    PDF Version
    03/29/21
    Summary ToggleHorizon Therapeutics and Chicago Cubs Announce Legacy Partnership
    PDF Version
    03/25/21
    Summary ToggleFirst Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout
    PDF Version
    03/24/21
    Summary ToggleUPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    03/24/21
    Summary ToggleHorizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community
    PDF Version
    Displaying 21 - 30 of 590 results